Abstract:Objectives: To investigate the mechanism of comorbidity between non-alcoholic fatty liver disease (NAFLD) and atherosclerosis (AS) based on metabolomics and network pharmacology. Methods: Six ApoE－/－ mice were fed with a high-fat diet for 16 weeks as a comorbid model of NAFLD and AS (model group). Normal diet was given to 6 wildtype C57BL/6J mice (control group). Serum samples were taken from both groups for a non-targeted metabolomics assay to identify differential metabolites. Network pharmacology was applied to explore the possible mechanistic effects of differential metabolites on AS and NAFLD. An in vitro comorbid cell model was constructed using NCTC1469 cells and RAW264.7 macrophage. Cellular lipid accumulation, cell viability, morphology and function of mitochondria were detected with oil red O staining, CCK-8 assay, transmission electron microscopy and JC-1 staining, respectively. Results: A total of 85 differential metabolites associated with comorbidity of NAFLD and AS were identified. The top 20 differential metabolites were subjected to network pharmacology analysis, which showed that the core targets of differential metabolites related to AS and NAFLD were STAT3, EGFR, MAPK14, PPARG, NFKB1, PTGS2, ESR1, PPARA, PTPN1 and SCD. The Kyoto Encyclopedia of Genes and Genomes showed the top 10 signaling pathways were PPAR signaling pathway, AGE-RAGE signaling pathway in diabetic complications, alcoholic liver disease, prolactin signaling pathway, insulin resistance, TNF signaling pathway, hepatitis B, the relax in signaling pathway, IL-17 signaling pathway and NAFLD. Experimental validation showed that lipid metabolism-related genes PPARG, PPARA, PTPN1, and SCD were significantly changed in hepatocyte models, and steatotic hepatocytes affected the expression of macrophage inflammation-related genes STAT3, NFKB1 and PTGS2; steatotic hepatocytes promoted the formation of foam cells and exacerbated the accumulation of lipids in foam cells; the disrupted morphology, impaired function, and increased reactive oxygen species production were observed in steatotic hepatocyte mitochondria, while the formation of foam cells aggravated mitochondrial damage. Conclusions: Abnormal lipid metabolism and inflammatory response are distinctive features of comorbid AS and NAFLD. Hepatocyte steatosis causes mitochondrial damage, which leads to mitochondrial dysfunction, increased reactive oxygen species and activation of macrophage inflammatory response, resulting in the acceleration of AS development.

Early Hyperlipidemia Triggers Metabolomic Reprogramming with Increased SAH, Increased Acetyl-Coa-cholesterol Synthesis, and Decreased Glycolysis.

Abstract 355: Cross-omics Identified That Early Hyperlipidemia Increased S-adenosylhomocysteine-hypomethylation and 24 Proinflammatory Metabolites May Synergize in Trained Immunity

Proteomic and Metabolomic Analyses of Atherosclerotic Vessels from Apolipoprotein E-Deficient Mice Reveal Alterations in Inflammation, Oxidative Stress, and Energy Metabolism

Hyperlipidemia May Synergize with Hypomethylation in Establishing Trained Immunity and Promoting Inflammation in NASH and NAFLD

Both gut microbiota and cytokines act to atherosclerosis in ApoE -/- mice

Dietary Sterols and Sterol Oxidation Products on Atherosclerosis: an Insight Provided by Liver Proteomic and Lipidomic.

LEHyperlipidemia May Synergize with Hypomethylation in Establishing Trained Immunity and Promoting Inflammation in NASH and NAFLD

Metabonomic Changes Associated with Atherosclerosis Progression for LDLR(-/-) Mice.

Early intermittent hyperlipidaemia alters tissue macrophages to fuel atherosclerosis

Modulation of cardiac resident macrophages immunometabolism upon high-fat-diet feeding in mice

Metabolic Profiling of Murine Plasma Reveals Eicosapentaenoic Acid Metabolites Protecting Against Endothelial Activation and Atherosclerosis.

Abstract 371: Deficiency in Microrna-155 Leads to Reduced Atherosclerosis, Increased Obesity and Nonalcoholic Fatty Liver Disease--A Novel Mouse Model of Metabolically Healthy Obesity

Proteomic And Metabolomic Analysis Of Smooth Muscle Cells Derived From The Arterial Media And Adventitial Progenitors Of Apolipoprotein E-Deficient Mice

Effects of apolipoprotein H downregulation on lipid metabolism, fatty liver disease, and gut microbiota dysbiosis

Untargeted Lipidomic Profiling Reveals Lysophosphatidylcholine and Ceramide as Atherosclerotic Risk Factors in apolipoprotein E Knockout Mice

Increased Acetylation of H3K14 in the Genomic Regions That Encode Trained Immunity Enzymes in Lysophosphatidylcholine-Activated Human Aortic Endothelial Cells – Novel Qualification Markers for Chronic Disease Risk Factors and Conditional DAMPs

Hepatocyte steatosis activates macrophage inflammatory response accelerating atherosclerosis development

Comprehensive lipidomics in apoM mice reveals an overall state of metabolic distress and attenuated hepatic lipid secretion into the circulation

Mitochondrial Metabolic Reprogramming by CD36 Signaling Drives Macrophage Inflammatory Responses

Metabolic shifts toward fatty-acid usage and increased thermogenesis are associated with impaired adipogenesis in mice expressing human APOE4

Unveiling the Impact of ApoF Deficiency on Liver and Lipid Metabolism: Insights from Transcriptome-Wide m6A Methylome Analysis in Mice